{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:58:56Z","timestamp":1780894736452,"version":"3.54.1"},"reference-count":149,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis, despite significant research efforts. The use of radiotherapy (RT) in PDAC treatment is constrained by intrinsic PDAC radioresistance and concern for normal tissue toxicity. Radiogenomics, the study of how genetic variants may influence RT response, could be incorporated into PDAC treatment. This approach offers a framework for personalized RT dosing guided by individual genomic data. Additionally, DNA damage response (DDR) inhibitors may sensitize PDAC to ionizing radiation to increase the targeted effectiveness of RT. This review examines the history and progress of radiogenomics, spanning from genome-wide approaches to more recent algorithm-based indices such as the radiosensitivity index (RSI) and the genomic-adjusted radiation dose (GARD). These approaches are promising but require additional validation in PDAC due to inconsistent findings across studies and inadequate PDAC-specific data. We also evaluate clinical advances in the development of inhibitors targeting key DDR elements such as ATR, ATM, CHK1\/2, WEE1, DNA-PKcs, and PARP. Finally, we highlight emerging strategies for targeting KRAS G12D in PDAC. Collectively, these approaches offer an avenue for reducing radioresistance in PDAC while improving treatment response and minimizing normal tissue toxicity. Future research directions should include the incorporation of multi-omics data into predictive models for appropriate treatment selection, additional large-scale, biomarker-driven clinical trials, and continued integration of biomarker-targeting drug therapy, radiotherapy, and immunotherapy into treatment regimens.<\/jats:p>","DOI":"10.3389\/fonc.2026.1762867","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:42Z","timestamp":1780892622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Marie Nour","family":"Karam","sequence":"first","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hajj","sequence":"additional","affiliation":[{"name":"Heart, Vascular, and Thoracic Institute, Cleveland Clinic Foundation","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ramia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Geara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Hamadeh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob G.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic Foundation","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Grobmyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Almond","sequence":"additional","affiliation":[{"name":"M42","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2015.05.006","article-title":"The prediction of radiotherapy toxicity using single nucleotide polymorphism-based models: A step toward prevention","volume":"25","author":"Kerns","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2014.02.001","article-title":"Finding the genetic determinants of adverse reactions to radiotherapy","volume":"26","author":"Rattay","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150172","article-title":"Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment","volume":"88","author":"Scaife","year":"2015","journal-title":"Br J Radiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: Current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int J Med Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3007","article-title":"Strategies to improve radiotherapy with targeted drugs","volume":"11","author":"Begg","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.035","article-title":"Radiogenomics - current status, challenges and future directions","volume":"382","author":"Andreassen","year":"2016","journal-title":"Cancer Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602577","article-title":"Intensity-modulated radiation therapy: Emerging cancer treatment technology","volume":"92","author":"Hong","year":"2005","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrclinonc.2009.188","article-title":"Stereotactic body radiation therapy: A novel treatment modality","volume":"7","author":"Lo","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.353","article-title":"Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061206","article-title":"Adaptive radiotherapy: Next-generation radiotherapy","volume":"16","author":"Dona Lemus","year":"2024","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152596","article-title":"Multi-institutional comparison of ablative 5-fraction magnetic resonance-guided online adaptive versus 15\/25-fraction computed tomography-guided moderately hypofractionated offline adapted radiation therapy for locally advanced pancreatic cancer","volume":"17","author":"Chuong","year":"2025","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091580","article-title":"Particle therapy to overcome cancer radiation resistance: \u201cArChade\u201d consortium updates in radiation biology","volume":"17","author":"Valable","year":"2025","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-019-02028-w","article-title":"Radiogenomics: Bridging imaging and genomics","volume":"44","author":"Bodalal","year":"2019","journal-title":"Abdominal Radiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0795-6","article-title":"Combining molecular and imaging metrics in cancer: Radiogenomics","volume":"11","author":"Lo Gullo","year":"2020","journal-title":"Insights into Imaging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.radonc.2009.06.015","article-title":"Genetic variants and normal tissue toxicity after radiotherapy: A systematic review","volume":"92","author":"Andreassen","year":"2009","journal-title":"Radiother Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"Tam","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43586-021-00056-9","article-title":"Genome-wide association studies","volume":"1","author":"Uffelmann","year":"2021","journal-title":"Nat Rev Methods Primers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.07.036","article-title":"Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer","volume":"78","author":"Kerns","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.08.003","article-title":"A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer","volume":"85","author":"Kerns","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.01.096","article-title":"A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer","volume":"190","author":"Kerns","year":"2013","journal-title":"J Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.05.001","article-title":"Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer","volume":"107","author":"Kerns","year":"2013","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3020","article-title":"A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1","volume":"46","author":"Fachal","year":"2014","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz075","article-title":"Radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy","volume":"112","author":"Kerns","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01670-w","article-title":"A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis","volume":"126","author":"Schack","year":"2022","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109806","article-title":"Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer","volume":"187","author":"Jandu","year":"2023","journal-title":"Radiother Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.10.012","article-title":"Beyond GWASs: Illuminating the dark road from association to function","volume":"93","author":"Edwards","year":"2013","journal-title":"Am J Hum Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ijrobp.2009.05.056","article-title":"Systems biology modeling of the radiation sensitivity network: A biomarker discovery platform","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.014","article-title":"A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5437","article-title":"The radiosensitivity index predicts for overall survival in glioblastoma","volume":"6","author":"Ahmed","year":"2015","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-0891","article-title":"Validation of a radiosensitivity molecular signature in breast cancer","volume":"18","author":"Eschrich","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.06.021","article-title":"Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer","volume":"93","author":"Torres-Roca","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.07.018","article-title":"Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer","volume":"117","author":"Strom","year":"2015","journal-title":"Radiother Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ijrobp.2019.11.013","article-title":"Using the radiosensitivity index (RSI) to predict pelvic failure in endometrial cancer treated with adjuvant radiation therapy","volume":"106","author":"Mohammadi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-8140(21)01970-8","article-title":"The radiosensitivity index predicts benefit from HDR brachytherapy in high-risk prostate cancer","volume":"152","author":"Thiruthaneeswaran","year":"2020"},{"key":"B37","doi-asserted-by":"publisher","first-page":"01tr","DOI":"10.1088\/1361-6560\/aaf26a","article-title":"The linear quadratic model: Usage, interpretation and challenges","volume":"64","author":"McMahon","year":"2018","journal-title":"Phys Med Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.08.019","article-title":"Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management","volume":"47","author":"Ahmed","year":"2019","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30648-9","article-title":"A genome-based model for adjusting radiotherapy dose (GARD): A retrospective, cohort-based study","volume":"18","author":"Scott","year":"2017","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): A cohort-based pooled analysis","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194073","article-title":"Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose","volume":"135","author":"Ho","year":"2025","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005, a randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.008","article-title":"Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in NSCLC","volume":"16","author":"Scott","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30698-8","article-title":"Future cancer research priorities in the USA: A Lancet Oncology commission","volume":"18","author":"Jaffee","year":"2017","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2020.02.050","article-title":"The European Organisation for Research and Treatment of Cancer, state of science in radiation oncology and priorities for clinical trials meeting report","volume":"131","author":"Thomas","year":"2020","journal-title":"Eur J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.02.018","article-title":"Radiosensitivity index is not fit to be used for dose adjustments: A pan-cancer analysis","volume":"35","author":"Mistry","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31821268d1","article-title":"Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer","volume":"40","author":"Zeng","year":"2011","journal-title":"Pancreas"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191936","article-title":"Pancreatic ductal adenocarcinoma: The Everest of cancer biology","volume":"135","author":"Than","year":"2025","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"8971","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"Aran","year":"2015","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1118\/1.3157095","article-title":"The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery","volume":"36","author":"Kirkpatrick","year":"2009","journal-title":"Med Phys"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7013","article-title":"Clinical impact of local progression in pancreatic cancer","volume":"16","author":"Cardillo","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010102","article-title":"Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization","volume":"17","author":"Maier","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205015","article-title":"Targeting KRAS in pancreatic ductal adenocarcinoma: The long road to cure","volume":"15","author":"de Jesus","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-05-0158","article-title":"Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-Ras","volume":"65","author":"Brunner","year":"2005","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbcan.2017.02.003","article-title":"Biological determinants of radioresistance and their remediation in pancreatic cancer","volume":"1868","author":"Seshacharyulu","year":"2017","journal-title":"Biochim Biophys Acta (BBA)  Rev Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031701","article-title":"Therapeutic targeting of DNA damage response in cancer","volume":"23","author":"Choi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: Making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110473","article-title":"Dosimetric predictors of acute and late gastrointestinal toxicities in stereotactic online adaptive magnetic resonance-guided radiotherapy (SMART) for locally advanced pancreatic adenocarcinoma","volume":"200","author":"D'Souza","year":"2024","journal-title":"Radiother Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01469-9","article-title":"BRCA-mutant pancreatic ductal adenocarcinoma","volume":"125","author":"Lai","year":"2021","journal-title":"Br J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01604","article-title":"Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211014818","article-title":"The role of PARP inhibitors in BRCA mutated pancreatic cancer","volume":"14","author":"Chi","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.297","article-title":"Phase II study of olaparib for BRCAness phenotype in pancreatic cancer","volume":"36","author":"Golan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu581","article-title":"Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer","volume":"26","author":"Bendell","year":"2015","journal-title":"Ann Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: A randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00316","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/genes12081229","article-title":"Guardians of the genome: BRCA2 and its partners","volume":"12","author":"Le","year":"2021","journal-title":"Genes"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00707","article-title":"Synthetic lethality triggered by combining olaparib with BRCA2\u2013RAD51 disruptors","volume":"12","author":"Falchi","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejmech.2019.01.008","article-title":"RAD51\/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells","volume":"165","author":"Roberti","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01526","article-title":"Synthetic lethality in pancreatic cancer: Discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparib","volume":"63","author":"Bagnolini","year":"2020","journal-title":"J Med Chem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116114","article-title":"An (19)F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer","volume":"265","author":"Myers","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B78","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41467-025-66694-9","article-title":"Computationally-designed aptamers targeting RAD51-BRCA2 interaction impair homologous recombination and induce synthetic lethality","volume":"17","author":"Milordini","year":"2025","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117372","article-title":"Structure-based design, synthesis and biological evaluation of a novel D-amino acid-containing peptide inhibitor by blocking the RAD51-BRCA2 interaction for the treatment of kidney cancer","volume":"287","author":"Wang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B80","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.chembiol.2021.02.006","article-title":"A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death","volume":"28","author":"Scott","year":"2021","journal-title":"Cell Chem Biol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41420-025-02382-3","article-title":"Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity","volume":"11","author":"Masi","year":"2025","journal-title":"Cell Death Discov"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/genes7090063","article-title":"Reappearance from obscurity: Mammalian RAD52 in homologous recombination","volume":"7","author":"Hanamshet","year":"2016","journal-title":"Genes (Basel)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.034","article-title":"Simultaneous targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells","volume":"23","author":"Sullivan-Reed","year":"2018","journal-title":"Cell Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030527","article-title":"Radiosensitizing pancreatic cancer with PARP inhibitor and gemcitabine: An in vivo and a whole-transcriptome analysis after proton or photon irradiation","volume":"13","author":"Waissi","year":"2021","journal-title":"Cancers"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4161\/cc.10.24.18661","article-title":"Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1","volume":"10","author":"Vance","year":"2011","journal-title":"Cell Cycle"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110310","article-title":"The expanding role of Wee1","volume":"94","author":"Koh","year":"2022","journal-title":"Cell Signal"},{"key":"B87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","article-title":"Wee1 inhibitor: Clinical development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-10-2580","article-title":"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts","volume":"17","author":"Rajeshkumar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00965-7","article-title":"A phase Ib study assessing the safety, tolerability, and efficacy of the first-in-class Wee1 inhibitor adavosertib (AZD1775) as monotherapy in patients with advanced solid tumors","volume":"18","author":"Bauer","year":"2023","journal-title":"Target Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4009","article-title":"Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors","volume":"33","author":"Do","year":"2015","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","article-title":"A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors","volume":"41","author":"Falchook","year":"2023","journal-title":"Invest New Drugs"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00730","article-title":"Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4211","article-title":"Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer","volume":"42","author":"Huffman","year":"2024","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5634","article-title":"Debio 0123, a highly selective Wee1 inhibitor in adult patients with advanced solid tumors: A phase 1 dose escalation and expansion monotherapy study","volume":"43","author":"Rubinstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02904-3","article-title":"ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment","volume":"132","author":"Bruciamacchie","year":"2025","journal-title":"Br J Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-18-0010","article-title":"The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.3067","article-title":"Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors","volume":"37","author":"Mittra","year":"2019","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the Atr inhibitor berzosertib (formerly M6620, Vx-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1078-0432.CCR-24-1867","article-title":"A translational study of the Atr inhibitor berzosertib as monotherapy in four molecularly defined cohorts of advanced solid tumors","volume":"31","author":"Cote","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT222","article-title":"Abstract Ct222: Efficacy and safety of ceralasertib in the Planette study in patients (Pts) with Atm-altered advanced solid tumors (Asts) or metastatic castration-resistant prostate cancer (Mcrpc)","volume":"84","author":"Aggarwal","year":"2024","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel Atr inhibitor Bay 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B105","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and Rad3-related (Atr) inhibitor Bay 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-1016-2","article-title":"Complete loss of Atm function augments replication catastrophe induced by Atr inhibition and gemcitabine in pancreatic cancer models","volume":"123","author":"Dunlop","year":"2020","journal-title":"Br J Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.183","article-title":"Therapeutic co-targeting of Wee1 and Atm downregulates Pd-L1 expression in pancreatic cancer","volume":"52","author":"Jin","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-21-0934","article-title":"A new class of selective Atm inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-17-A094","article-title":"Abstract A094: Phase I modular study of Azd0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (Atm), in combination with olaparib (Atom study, module 1)","volume":"17","author":"Abida","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT171","article-title":"Abstract Ct171: A first-in-human phase I study of the Atm inhibitor M4076 in patients with advanced solid tumors (Ddriver solid tumors 410): Part 1a results","volume":"83","author":"Siu","year":"2023","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0890","article-title":"A novel dual Atm\/DNA-Pk inhibitor, Xrd-0394, potently radiosensitizes and potentiates Parp and topoisomerase I inhibitors","volume":"23","author":"Gilmer","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-LB181","article-title":"Abstract Lb181: First disclosure of Xrd-0394, a novel dual Atm\/DNA-Pk inhibitor, that potently radiosensitizes and potentiates Parp and topoisomerase inhibitors","volume":"84","author":"Gilmer","year":"2024","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i32.7275","article-title":"Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor Mk-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","article-title":"A phase 1\/2 trial of Sra737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","volume":"129","author":"Kristeleit","year":"2023","journal-title":"Br J Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A phase I\/II trial of oral Sra737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-3631","article-title":"Abstract 3631: Preclinical and clinical pharmacodynamic characterization of Bbi-355, a novel, orally bioavailable, and selective Chk1 inhibitor being evaluated in the first-in-human phase 1\/2 Potentiate clinical trial of patients with cancer harboring oncogene amplifications","volume":"84","author":"Liao","year":"2024","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-613","article-title":"Abstract 613: Oral Chk1 inhibitor Bbi-355 allows flexibility of dose and schedule with demonstration of monotherapy and combinational antitumor activity in extrachromosomal DNA (Ecdna) driven preclinical models","volume":"84","author":"Hansen","year":"2024","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.05.052","article-title":"Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of Hr in mid S phase","volume":"47","author":"Karanam","year":"2012","journal-title":"Mol Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.11920","article-title":"Ku autoantigen is the regulatory component of a template-associated protein kinase that phosphorylates Rna polymerase II","volume":"89","author":"Dvir","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90057-w","article-title":"The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen","volume":"72","author":"Gottlieb","year":"1993","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.07.029","article-title":"DNA-Pk inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-Pk, M3814, potentiates radiotherapy and regresses human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0725","article-title":"DNA-Pk inhibition and radiation promote antitumoral immunity through Rna polymerase III in pancreatic cancer","volume":"20","author":"Wang","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01151-6","article-title":"A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor Peposertib (formerly M3814) in patients with advanced solid tumours","volume":"124","author":"van Bussel","year":"2021","journal-title":"Br J Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102217","article-title":"Phase I study of Peposertib and Avelumab with or without palliative radiotherapy in patients with advanced solid tumors","volume":"9","author":"Perez","year":"2024","journal-title":"ESMO Open"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4168","article-title":"Etctn 10366: A phase 1 study of DNA-Pk inhibitor Peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma","volume":"42","author":"Davis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"Kras mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jgo.2017.10.14","article-title":"A Kras wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma","volume":"9","author":"Windon","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab871","article-title":"Oncogenic Kras drives radioresistance through upregulation of Nrf2-53bp1-mediated non-homologous end-joining repair","volume":"49","author":"Yang","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1104437","article-title":"Mek inhibitor Gsk1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways","volume":"14","author":"Estrada-Bernal","year":"2015","journal-title":"Cell Cycle"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, Mkras-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 Amplify-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.023","article-title":"Radiation therapy and the in situ vaccination approach","volume":"108","author":"Golden","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-21-0612","article-title":"DNA-Pk inhibitor Peposertib amplifies radiation-induced inflammatory micronucleation and enhances Tgf\u03b2\/Pd-L1 targeted cancer immunotherapy","volume":"20","author":"Carr","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-19-0761","article-title":"Inhibition of Atm increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.168824","article-title":"Potentiating the radiation-induced type I interferon antitumoral immune response by Atm inhibition in pancreatic cancer","volume":"9","author":"Zhang","year":"2024","journal-title":"JCI Insight"},{"key":"B137","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-59038-3_15","article-title":"Pancreatic tumor microenvironment","volume-title":"Tumor Microenvironments in Organs: From the Brain to the Skin \u2013 Part B","author":"Wang","year":"2020"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-019-0226-9","article-title":"Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma","volume":"8","author":"Daniel","year":"2019","journal-title":"Clin Transl Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00570","article-title":"Therapeutic potential of combining Parp inhibitor and immunotherapy in solid tumors","volume":"10","author":"Vikas","year":"2020","journal-title":"Front Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.024","article-title":"Stromal Hif2 regulates immune suppression in the pancreatic cancer microenvironment","volume":"162","author":"Garcia Garcia","year":"2022","journal-title":"Gastroenterology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1200\/po.19.00086","article-title":"Biomarker-driven oncology clinical trials: Key design elements, types, features, and practical considerations","volume":"3","author":"Hu","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: A systematic review and prevalence meta-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","article-title":"Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma","volume":"160","author":"Golan","year":"2021","journal-title":"Gastroenterology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/sla.0000000000006209","article-title":"Prospective evaluation of circulating tumor DNA using next-generation sequencing as a biomarker during neoadjuvant chemotherapy in localized pancreatic cancer","volume":"281","author":"Shah","year":"2025","journal-title":"Ann Surg"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2013.049","article-title":"New possibilities and potential benefits for local control in locally recurrent pancreatic cancer","volume":"4","author":"Lloyd","year":"2013","journal-title":"J Gastrointest Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1211","article-title":"Determining target engagement in living systems","volume":"9","author":"Simon","year":"2013","journal-title":"Nat Chem Biol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01102-8","article-title":"Adavosertib in combination with olaparib in patients with refractory solid tumors: An open-label, dose-finding, and dose-expansion phase Ib trial","volume":"19","author":"Hamilton","year":"2024","journal-title":"Target Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11523-020-00701-5","article-title":"Safety, pharmacokinetics, and clinical activity of adavosertib in combination with chemotherapy in Asian patients with advanced solid tumors: Phase Ib study","volume":"15","author":"Kato","year":"2020","journal-title":"Target Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.5991","article-title":"Phase I study evaluating Wee1 inhibitor Azd1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1762867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:45Z","timestamp":1780892625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1762867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":149,"alternative-id":["10.3389\/fonc.2026.1762867"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1762867","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1762867"}}